Biosimilars

Brain Cancer

Neoadjuvant HER2+

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immunotherapy in GU Cancers

Immunotherapy in Lung Cancer

Immunotherapy in Melanoma

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Oncology Nursing News

Pediatric Oncology

Special Reports in Personalized Cancer Care

Precision Medicine in Oncology®

Sarcomas/TGCT

Supportive Care

Julia Rotow, MD, discusses the importance of comprehensive biomarker testing for all patients with NSCLC.

Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes

Joshua K. Sabari, MD, discusses barriers to biomarker testing in patients with non–small cell lung cancer.

Dr Sabari on Barriers to Biomarker Testing in NSCLC

Leah Backhus, MD, MPH, FACS, discusses the evolving definition of surgical resectability in patients with borderline resectable NSCLC.

Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC

Roy S. Herbst, MD, PhD, discusses the importance of consulting a multidisciplinary tumor board when making treatment decisions for patients with NSCLC.

Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

Articles

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

Blinatumomab added to consolidation chemotherapy led to a significant OS benefit in MRD-negative B-cell precursor acute lymphoblastic leukemia.

Blinatumomab Plus Consolidation Chemotherapy Extends OS in MRD– B-Cell Precursor ALL

Paolo Tarantino, MD, discusses questions about the optimal sequencing of antibody-drug conjugates in endocrine-refractory, HR-positive breast cancer. 

Pending Dato-DXd Approval Solidifies Importance of Sequencing in HR+ Breast Cancer 

Shubham Pant, MD, MBBS, discusses findings from the phase 2b HERIZON-BTC-01 study of zanidatamab in pretreated HER2-positive biliary tract cancer.

Zanidatamab Demonstrates Activity in Pretreated HER2+ Biliary Tract Cancer

Eileen M. O'Reilly, MD, details how RAS-directed therapy could potentially change the pancreatic cancer landscape and highlights updated data in the space.

RAS-Directed Therapy and Patient Selection Are Sectors to Watch in Pancreatic Cancer 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

ASK THE EXPERTS: Advanced Neuroimaging of Glioblastoma

Clinical

Video Series

Neuroimaging of Glioblastoma

Videos

Nathalie Albert, MD, and Matthias Preusser, MD, explore the latest advancements in neuroimaging technologies and techniques, focusing on the use of amino acid tracers to enhance the diagnosis, treatment, and overall care of patients with glioblastoma.

Nathalie Albert, MD, and Matthias Preusser, MD engage in an interactive discussion about the primary challenges in neuroimaging for glioblastoma patients and provide an overview of the disease.  

Neuroimaging of Glioblastoma 

Key opinion leaders discuss the patient journey, highlighting the clinical course of the disease and the corresponding imaging needs at each stage, such as identification of biopsy site, delineation of tumor, and differentiation of response from treatment-related effects.  

Navigating Glioblastoma Imaging: The Patient Journey from Diagnosis to Treatment 

Medical experts discuss the use of various neuroimaging techniques, such as MRIs, CT scans, and PET scans, emphasizing that due to limitations of MRI it is frequently combined with other modalities to obtain more comprehensive information.

Leveraging Neuroimaging Modalities and Guidelines in Glioblastoma

Experts engage in a comprehensive discussion on conventional imaging techniques, evaluating the strengths and limitations of CT and MRI scans, particularly in delineating tumor borders and distinguishing between tumors and the surrounding central nervous system tissue.

Conventional Neuroimaging: CT scans & MRI Scans in Glioblastoma

Nathalie Albert, MD, delves into advanced MRI techniques such as perfusion imaging, functional MRI, MR spectroscopy, and DEMARCATE, while also exploring the role of PET imaging, particularly those utilizing glucose and amino acid tracers in neuroimaging.

Advanced Modalities of Neuroimaging in the Management of Glioblastoma

Nathalie Albert, MD, explains that amino acid PET scans can be valuable tools in monitoring disease progression and assessing a patient's response to treatment, while also exploring the optimal timing for utilizing these scans in the overall management of brain tumors.

Polling Question: Utility of Amino Acid PET

Medical experts engage in a discussion on the PET RANO 1.0 Response Criteria, which provides guidelines for evaluating treatment response in patients with brain tumors, taking into account both measurable PET-positive disease and non-PET-positive disease, as assessed through initial baseline imaging and subsequent follow-up scans. 

Implementing PET RANO 1.0 Response Criteria in Glioblastoma Assessment 

Nathalie Albert, MD, and Matthias Preusser, MD, address audience questions and share their insights on promising and anticipated advancements in neuroimaging techniques, highlighting the potential impact of these emerging strategies on the diagnosis, monitoring, and treatment of glioblastoma. 

Q&A: Final Questions on Glioblastoma and Neuroimaging  

Neuroimaging of Glioblastoma

EP: 1.Neuroimaging of Glioblastoma

EP: 2.Navigating Glioblastoma Imaging: The Patient Journey from Diagnosis to Treatment

EP: 3.Leveraging Neuroimaging Modalities and Guidelines in Glioblastoma

EP: 4.Conventional Neuroimaging: CT scans & MRI Scans in Glioblastoma

EP: 5.Advanced Modalities of Neuroimaging in the Management of Glioblastoma

EP: 6.Polling Question: Utility of Amino Acid PET

EP: 7.Implementing PET RANO 1.0 Response Criteria in Glioblastoma Assessment

EP: 8.Q&A: Final Questions on Glioblastoma and Neuroimaging

Latest Conference Coverage